Clinical Trial Update: High-Risk Metachronous Oligometastatic Prostate Cancer Trial [Phase 2]

View source ↗

Summary

Phase 2 trial investigating high-risk metachronous oligometastatic prostate cancer is currently recruiting, sponsored by the University of Maryland, Baltimore.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Prostate Cancer, Oligometastatic Disease | Phase 2 | Status: RECRUITING